Coumarins as anti-HIV agent and correlation with COVID-19: an overview

被引:0
作者
Kumar, Vikas [1 ]
Joshi, Harish Chandra [2 ]
Pandey, Inder Prasad [1 ]
Kumar, Sanjay [3 ]
机构
[1] Uttarakhand Tech Univ, Dept Chem, Dehra Dun, Uttarakhand, India
[2] Graph Era Deemed Univ, Dept Chem, Dehra Dun, Uttarakhand, India
[3] Graph Era Deemed Univ, Dept Food Tech, Dehra Dun, Uttarakhand, India
来源
HIV & AIDS REVIEW | 2023年 / 22卷 / 02期
关键词
anti -HIV agent; coumarin; calanoide; COVID-19; HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; NATURAL-PRODUCTS; MACROCYCLIC PEPTIDES; PROTEASE INHIBITORS; AIDS AGENTS; TYPE-1; FUSION; GP41; DERIVATIVES;
D O I
10.5114/hivar.2023.127276
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Acquired immunodeficiency syndrome (AIDS) is an immunosuppressive disease caused by human immunodeficiency virus (HIV), and leads to infection and malignance, which are life threatening. HIV/AIDS cause numerous deaths in Africa, and is the leading cause of death in India, affecting every fourth living HIV patient. The amount in Southeast Asia is increasing at alarming rate. In this paper, the current issue of COVID-19 and its' possible target of HIV drugs that inhibit entry of the virus into host cell were investigated. Three main groups of coronavirus are surrounded by spike genes, showing that for fusion mechanism, these groups are common mode for attachment. For nearly all disease areas, plant kingdom biodiversity provides a source of new drug candidates. There is a continuous increase in various compounds with anti-HIV activity isolated from natural sources. Various literature and current COVID-19 pandemic situation were considered in the present report. Phase II clinical candidates are calanolide A, a coumarins isolated from Calophyllum lanigerum, and two other natural product-derived molecules, such as DSB and 3-hydroxymethyl-4-methyl DCK, with a potential to emerge as HIV therapy drugs. This naturally obtained product with anti-HIV properties was described in the present paper, focusing on current results as anti-HIV agents derived from natural sources.
引用
收藏
页码:87 / 98
页数:12
相关论文
共 50 条
  • [41] Overview of management of children with COVID-19
    Wati, Dyah Kanya
    Manggala, Arya Krisna
    CLINICAL AND EXPERIMENTAL PEDIATRICS, 2020, 63 (09) : 345 - 354
  • [42] An overview on COVID-19: reality and expectation
    Manal A. Hamed
    Bulletin of the National Research Centre, 44 (1)
  • [43] COVID-19: Overview of rheumatology fellows
    Garcia-Guillen, Andrea
    Jeria, Sicylle
    Lobo-Prat, David
    Sainz, Luis
    REUMATOLOGIA CLINICA, 2021, 17 (09): : 491 - 493
  • [44] COVID-19: molecular diagnostics overview
    Marlin Touma
    Journal of Molecular Medicine, 2020, 98 : 947 - 954
  • [45] Quinolone derivatives: Potential anti-HIV agent-development and application
    Wang, Ruo
    Xu, Kai
    Shi, Weixiong
    ARCHIV DER PHARMAZIE, 2019, 352 (09)
  • [46] Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes
    Dubey, Vaibhav
    Mishra, Dinesh
    Nahar, Manoj
    Jain, Vikas
    Jain, Narendra Kumar
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2010, 6 (04) : 590 - 596
  • [47] Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?
    Nasiripour, Somayyeh
    Zamani, Farhad
    Farasatinasab, Maryam
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07) : 828 - 829
  • [48] Role of chest radiography in the management of COVID-19 pneumonia: An overview and correlation with pathophysiologic changes
    Kohli, Anirudh
    Hande, Pradipta C.
    Chugh, Shivam
    INDIAN JOURNAL OF RADIOLOGY AND IMAGING, 2021, 31 (05) : S70 - S79
  • [49] HIV and COVID-19: review of clinical course and outcomes
    Barbera, Lauren K.
    Kamis, Kevin F.
    Rowan, Sarah E.
    Davis, Amelia J.
    Shehata, Soraya
    Carlson, Jesse J.
    Johnson, Steven C.
    Erlandson, Kristine M.
    HIV RESEARCH & CLINICAL PRACTICE, 2021, 22 (04) : 102 - 118
  • [50] The effects of the COVID-19 pandemic on people living with HIV
    Walker, S. H.
    Grierson, J.
    Sullivan, A.
    Alagaratnam, J.
    HIV MEDICINE, 2025, 26 (03) : 479 - 488